Klisyri

Tirbanibulin, the active ingredient in Klisyri, is a Src kinase inhibitor presented as a 1% topical solution for topical use. It is indicated for the field‑directed treatment of actinic keratosis on the face and scalp in adult patients, providing a non‑surgical option to remove precancerous skin lesions and reduce the risk of progression to invasive cancer.

GNH USA supplies Klisyri as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled distribution across EU and other regulated markets while adhering to stringent regulatory standards.

Klisyri (tirbanibulin) is a topical antineoplastic agent used in the management of actinic keratosis, a precancerous skin condition. - Actinic keratosis (face and scalp): clears precancerous lesions and lowers the likelihood of progression to squamous cell carcinoma.

Klisyri may cause local skin reactions that are generally mild to moderate.

Common Side Effects: - Erythema: redness at the application site. - Crusting: formation of dry scabs. - Scaling: flaking of treated skin. - Itching: mild to moderate pruritus. - Pain or burning: transient discomfort. - Dryness: reduced skin moisture.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, hives, or difficulty breathing. - Contact dermatitis: intense irritation or rash. - Secondary infection: signs of bacterial or fungal involvement. - Ulceration: breakdown of skin tissue. - Persistent edema: prolonged swelling. - Systemic hypersensitivity: rare systemic immune response.

Before prescribing Klisyri, clinicians should consider patient‑specific factors and monitor for adverse reactions. - Contraindication: Known hypersensitivity to tirbanibulin or any excipient. - Application area: Avoid use on broken, inflamed, or infected skin. - Mucosal surfaces: Do not apply to eyes, mouth, or genital mucosa. - Pregnancy and lactation: Safety not established; use only if benefit outweighs risk. - Pediatric use: Not established; limited to adult patients. - Store below 25°C: keep in the original container, protect from light and moisture.

Topical tirbanibulin has limited systemic drug‑interaction potential, but co‑administration with certain agents may affect tolerability.

Major Interactions (Avoid): - Concurrent use of other topical antineoplastic agents on the same area: increased risk of severe skin toxicity. - Known allergy to formulation components: may trigger severe dermatitis.

Moderate Interactions (Monitor Closely): - Co‑application with keratolytic agents (e.g., salicylic acid): may enhance irritation. - Use with topical corticosteroids: could mask early signs of adverse skin reactions. - Photosensitizing drugs (e.g., tetracyclines): may increase sun‑induced skin sensitivity. - Systemic immunosuppressants: monitor for delayed wound healing. - Over‑the‑counter moisturizers containing irritants: assess for additive irritation.